Liposarcoma of Soft TissueNCT05428579
Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma
An observational study of Liposarcoma of Soft Tissue and Surgical Procedure, Unspecified, run by University of Sao Paulo General Hospital at 1 site in Brazil.
Trial summary
Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics. Read more about this study
- Who is it for?
- Ages 17 to 76 years
- Conditions the study is for
- Liposarcoma of Soft Tissue, Surgical Procedure, Unspecified
- What is being tested?
- Retroperitoneal Liposarcoma resection
- Type of treatment
- Surgery or procedure
- How many people
- 60 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Oct 2017to 1 Nov 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 76 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 60 patients attended at the University of São Paulo Medical School Hospital (HC-FMUSP) and the Cancer Institute of the State of São Paulo (ICESP) from 1997 to 2017, who underwent surgical resection of the primary tumor at these institutions, as well as those referred after resection at other services.
Who may be able to join
- All patients who underwent surgical resection of retroperitoneal liposarcoma
Who cannot join
- Unresectable disease (upper mesenteric artery or vein involvement) or metastatic disease (sarcomatosis or distant disease)
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, 05403000
About this study
Official title: Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma - Case Series
Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics. Objective: Evaluate variables that may be related to overall survival and local recurrence free survival in patients with retroperitoneal liposarcoma. Methods: retrospective analysis of medical records of 60 patients attended from 1997 to 2017, who underwent surgical resection of retroperitoneal liposarcoma.
- Being tested
- Retroperitoneal Liposarcoma resection
- Keywords
- retroperitoneal liposarcoma, overall survival, local recurrence free survival
- Medical subject headings
- Retroperitoneal liposarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Retroperitoneal Liposarcoma resectionProcedure or surgery
Retroperitoneal Liposarcoma resection
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival rate
Measured: 60 months
Local recurrence-free survival rate
Measured: 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2022
- Study start1 Oct 2017
- Primary completion1 Oct 2018
- Study completion1 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Liposarcoma of Soft TissueStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Edivaldo Massazo Utiyama, University of Sao Paulo General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05428579
- Sponsor's protocol ID
- 29071984
- Status last verified
- Jun 2022
- First submitted
- 9 Apr 2019
- Last updated
- 23 Jun 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Neuhaus SJ, Barry P, Clark MA, Hayes AJ, Fisher C, Thomas JM. Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg. 2005 Feb;92(2):246-52. doi: 10.1002/bjs.4802.
PubMed 15505870Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1. doi: 10.1097/01.sla.0000086542.11899.38.
PubMed 14501502
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma - Case Series
- ClinicalTrials.gov ID
- NCT05428579
- Acronym / sponsor ID
- 29071984
- Keywords
- retroperitoneal liposarcoma, overall survival, local recurrence free survival
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Study start
- 1 Oct 2017 (actual)
- Primary completion
- 1 Oct 2018 (actual)
- Study completion
- 1 Nov 2018 (actual)
- First posted
- 23 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics. Objective: Evaluate variables that may be related to overall survival and local recurrence free survival in patients with retroperitoneal liposarcoma. Methods: retrospective analysis of medical records of 60 patients attended from 1997 to 2017, who underwent surgical resection of retroperitoneal liposarcoma.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 17 to 76 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 60 patients attended at the University of São Paulo Medical School Hospital (HC-FMUSP) and the Cancer Institute of the State of São Paulo (ICESP) from 1997 to 2017, who underwent surgical resection of the primary tumor at these institutions, as well as those referred after resection at other services.
Key inclusion criteria (1 listed)
- All patients who underwent surgical resection of retroperitoneal liposarcoma
Key exclusion criteria (1 listed)
- Unresectable disease (upper mesenteric artery or vein involvement) or metastatic disease (sarcomatosis or distant disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Retroperitoneal Liposarcoma resectionRetroperitoneal Liposarcoma resection | Procedure or surgery | – |
Primary outcome
Overall survival rate
Time frame: 60 months
Local recurrence-free survival rate
Time frame: 60 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2022.
- Results publication: PubMed 15505870Neuhaus SJ, Barry P, Clark MA, Hayes AJ, Fisher C, Thomas JM. Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg. 2005 Feb;92(2):246-52. doi: 10.1002/bjs.4802.
- Results publication: PubMed 14501502Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1. doi: 10.1097/01.sla.0000086542.11899.38.
- Individual participant dataSharing planned: No
Related trials for Liposarcoma of Soft Tissue
RecruitingPhase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Active, not recruitingPhase 2
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Synovial Sarcoma, Myxoid Liposarcoma
RecruitingPhase 1
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Active, not recruitingPhase 2
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma
RecruitingPhase 1/2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Liposarcoma, Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liposarcoma of Soft Tissue and Surgical Procedure, Unspecified, run by University of Sao Paulo General Hospital at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival rate (time frame: 60 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05428579, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2022; AzTrials last refreshed its copy on 7 Nov 2026.